Compare BBD & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBD | KVUE |
|---|---|---|
| Founded | 1943 | 2022 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Specialty Chemicals |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6B | 33.1B |
| IPO Year | N/A | 2023 |
| Metric | BBD | KVUE |
|---|---|---|
| Price | $3.34 | $17.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $2.55 | ★ $20.31 |
| AVG Volume (30 Days) | 34.8M | ★ 35.2M |
| Earning Date | 02-06-2026 | 02-05-2026 |
| Dividend Yield | ★ 4.94% | 4.82% |
| EPS Growth | ★ 47.11 | 35.31 |
| EPS | 0.38 | ★ 0.75 |
| Revenue | ★ $16,507,289,161.00 | $15,006,000,000.00 |
| Revenue This Year | $78.18 | N/A |
| Revenue Next Year | $7.75 | $2.81 |
| P/E Ratio | ★ $8.17 | $23.02 |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $1.85 | $14.02 |
| 52 Week High | $3.77 | $25.17 |
| Indicator | BBD | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 55.71 |
| Support Level | $3.25 | $16.93 |
| Resistance Level | $3.40 | $17.48 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 32.56 | 50.71 |
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.